<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641015</url>
  </required_header>
  <id_info>
    <org_study_id>PR 223/15</org_study_id>
    <nct_id>NCT02641015</nct_id>
  </id_info>
  <brief_title>Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)</brief_title>
  <acronym>RESCUING</acronym>
  <official_title>A Retrospective Observational Study to Assess the Clinical Management and Outcomes of Hospitalised Patients With Complicated Urinary Tract Infection in Countries With High Prevalence of Multidrug Resistant Gram-negative Bacteria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AiCuris Anti-infective Cures GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bristol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigació Biomèdica de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective observational study to assess the clinical management and outcomes of
      hospitalised patients with complicated urinary tract infection in countries with high
      prevalence of multidrug resistant gram-negative bacteria (COMBACTE-MAGNET,WP5)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial resistance to antimicrobial drugs is a major public health problem. Of greatest
      concern is the rapid emergence and dissemination of resistance to third generation
      cephalosporins in Enterobacteriaceae, especially Escherichia coli and Klebsiella pneumoniae.
      This is frequently seen in association with resistance to other classes of antibiotics
      leading to a multidrug resistance (MDR) profile. These MDR isolates are often involved in
      complicated urinary tract infection (cUTI), and are associated with poor clinical outcomes.
      In addition, in the last decade there has been an emergence of carbapenemase-producing
      Enterobacteriaceae, which are also resistant to other antibiotics than carbapenems, leaving
      few therapeutic options.

      The overall aim of this study is to provide information about the epidemiology, clinical
      management and outcome of patients hospitalised with cUTI, including pyelonephritis. To
      achieve this aim, the investigators will perform a multicentre retrospective observational
      study in patients with hospitalised cUTI. The study will be conducted in several European
      countries plus Israel, which have a high prevalence of MDR Gram-negative bacteria (GNB),
      including Pseudomonas aeruginosa. The study will seek to identify possible modifiable risk
      factors for treatment failure, especially those related to antibiotic therapy.

      On completion of this study, the investigators will develop a better understanding of the
      clinical management of hospitalised patients with cUTI due to MDR GNB in European countries.
      The investigators will identify the modifiable risk factors for treatment failure. This
      information will be used to inform better clinical and antibiotic management of cUTI to
      improve patient outcomes. The study will also be used in the development of hypothesis for
      future randomised controlled trials in cUTI with new antibiotics. Dissemination of results
      will take place through peer-reviewed publications and conference presentations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>30 days</time_frame>
    <description>Treatment failure will be assessed as number of participants with evidence of treatment failure or mortality within 30 days from initial cUTI diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical response</measure>
    <time_frame>30 days</time_frame>
    <description>Time to clinical response (in days), since initiation of antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to urological intervention for source control</measure>
    <time_frame>30 days</time_frame>
    <description>Time to urological intervention for source control (in days) since initial cUTI diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>30 days</time_frame>
    <description>Time to death (in days) since original cUTI diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic therapy</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of antibiotic therapy (in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of hospital stay (in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Hospital mortality during admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality within 30 days of the original cUTI diagnosis</measure>
    <time_frame>30 days</time_frame>
    <description>All cause mortality within 30 days of the original cUTI diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause of mortality for two months after hospital discharge</measure>
    <time_frame>60 days</time_frame>
    <description>All cause of mortality for two months after hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost per case of cUTI</measure>
    <time_frame>30 days</time_frame>
    <description>Cost per case of cUTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions to the hospital within 60 days of hospital discharge</measure>
    <time_frame>60 days</time_frame>
    <description>Readmissions to the hospital within 60 days of hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to antibiotic treatment including: moderate or severe allergic reactions, severe renal impairment, Clostridium difficile infection</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events related to antibiotic treatment including: moderate or severe allergic reactions, severe renal impairment, Clostridium difficile infection</description>
  </secondary_outcome>
  <enrollment type="Actual">1028</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Bacterial Resistance</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalised patients from 1st January 2013 to the 31st December 2014. Diagnosis of cUTI as
        the primary cause of hospitalisation and patients hospitalised for another reason but who
        developed cUTI during their hospitalisation. Patients will be identified by searching for
        any of the following ICD-9 CM or ICD-10 CM codes at discharge on the hospital
        administration system: ICD-9 CM Codes: 590.1, 590.10, 590.11, 590.2, 590.8, 590.80, 590.9,
        595.0, 595.89, 595.9, 99.0 ICD-10 CM Codes: N10, N12, N13.6, N15.1, N15.9, N30.0, N30.8,
        N30.9, N39.0
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with UTI and at least one of the following underlying conditions:

          -  Indwelling urinary catheter

          -  Urinary retention (at least 100ml of residual urine after voiding)

          -  Neurogenic bladder

          -  Obstructive uropathy (e.g. nephrolithiasis, fibrosis)

          -  Renal impairment caused by intrinsic renal disease: Estimated glomerular filtration
             rate (eGFR) &lt;60 mL/min

          -  Renal transplantation

          -  Urinary tract modifications, such as an ileal loop or pouch

          -  Pyelonephritis and normal urinary tract anatomy

        and at least one of the following signs or symptoms:

          -  Chills or rigors associated with fever or hypothermia (temperature greater than 38ºC
             or below 36ºC)

          -  Flank pain (pyelonephritis) or pelvic pain (cUTI)

          -  Dysuria, urinary frequency, or urinary urgency

          -  Costo-vertebral angle tenderness on physical examination

          -  UTI-related altered mental state

        and at least one of the following microbiological results:

          -  Urine culture with at least 105 CFU/mL or greater of a uropathogen (no more than 2
             species)

          -  At least one blood culture growing possible uropathogens (no more than 2 species) with
             no other evident site of infection

        Exclusion Criteria:

          -  Patients less than 18 years of age

          -  Prostatitis

          -  Polymicrobial infections that include Candida spp.

          -  Polymicrobial infections that include more than 2 bacterial species

          -  cUTI with Candida spp. as sole uropathogen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dora Tancheva, Mrs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Hospital Pirogov, Sofia, Bulgaria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rossitza Vatcheva-Dobrevska, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Queen Joanna, Sofia, Bulgaria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sotirios Tsiodras, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attikon University Hospital, Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel Roilides, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hippokration Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Istvan Vakonyi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenezy University Hospital,Debrecen, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aniko Farkas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház (SZSZBMK). Nyíregyháza, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Leibovici, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beilinson Hospital, Rabin Medical Center. Petah-TiqvaI, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mical Paul, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus. Haifa, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yehuda Carmeli, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Medical Center, Tel Aviv. Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emanuele Durante Mangoni, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>AORN dei Colli Monaldi. Napoli, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erica Franceschini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda ospedaliero-universitaria policlinico di modena, Modena, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Petrosillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Ursache, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Spitalul Clinic de Urgenta Bucuresti. Popular unoficial name &quot;&quot;Floreasca &quot;&quot; Hospital&quot;, Bucharest, Romania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judit BodnÃ¡r, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet, Sopron, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yehuda Carmeli, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Medical Center, Tel Aviv, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Vata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Hospital Sfanta Parascheva Iasi, Iasi, Romania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriana Hristea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Infectious Diseases Prof Dr Matei Bals, Bucharest, Romania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesus Rodriguez-Bano, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena, Seville, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia Origüen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arzu Yetkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara Numune Egitim ve ArastÄrma Hastanesi, Ankara, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nese Saltoglu, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University Cerrahpasa Medical School, Istambul, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miquel Pujol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emergency Hospital Pirogov</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Queen Joanna</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy University Hospital</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház (SZSZBMK)</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beilinson Hospital, Rabin Medical Center</name>
      <address>
        <city>Petah-Tiqva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico Di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN dei Colli Monaldi</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute for Infectious Diseases L. Spallanzani, IRCCS</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Spitalul Clinic de Urgenta Bucuresti. Popular unoficial name &quot;&quot;Floreasca &quot;&quot; Hospital&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute for Infectious Diseases Prof Dr Matei Bals</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Hospital Sfanta Parascheva Iasi</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet del Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Numune Egitim ve ArastÄ±rma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical School</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf</url>
    <description>UK Five Year Antimicrobial Resistance Strategy 2013-2018, September 2013.</description>
  </link>
  <link>
    <url>http://www.efsa.europa.eu/en/efsajournal/pub/3590</url>
    <description>The European Union Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2012</description>
  </link>
  <link>
    <url>http://uroweb.org/wp-content/uploads/19-Urological-infections_LR.pdf</url>
    <description>Guidelines on urological infections. European Association of Urology 2014</description>
  </link>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/Guidances/ucm070981.pdf</url>
    <description>Complicated Urinary Tract Infections: Developing Drugs for Treatment. Guidance for Industry (2015). U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER).</description>
  </link>
  <link>
    <url>http://icd9data.com/2015/volume1/580-629/default.htm</url>
    <description>International Classification of Diseases ICD-9 Data.</description>
  </link>
  <link>
    <url>http://apps.who.int/classifications/icd10/browse/2015/en</url>
    <description>International Statistical Classification of diseases and related Health Problems 10th Revision. ICD-10. Version 2015.</description>
  </link>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf</url>
    <description>European Medicines Agency (EMA). Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. December 2011. Committee for Medical Products for Human Use (CHMP).</description>
  </link>
  <link>
    <url>http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf</url>
    <description>Kidney Disease: Improving global outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney inter. Int Suppl. 2013; 3: 1-150.</description>
  </link>
  <link>
    <url>http://umm.edu/health/medical/reports/articles/urinary-tract-infection</url>
    <description>University of Maryland Medical Center. Urinary tract Infection</description>
  </link>
  <link>
    <url>http://eur-lex.europa.eu/legal-content/GA/ALL/?uri=OJ:L:1995:281:TOC</url>
    <description>Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data</description>
  </link>
  <reference>
    <citation>Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013 Nov 1;6(11):1335-46. doi: 10.3390/ph6111335.</citation>
    <PMID>24287460</PMID>
  </reference>
  <reference>
    <citation>Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M, Hawser S. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis. 2012 Sep;74(1):62-7. doi: 10.1016/j.diagmicrobio.2012.05.024. Epub 2012 Jul 2.</citation>
    <PMID>22763019</PMID>
  </reference>
  <reference>
    <citation>Yang YS, Ku CH, Lin JC, Shang ST, Chiu CH, Yeh KM, Lin CC, Chang FY. Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect. 2010 Jun;43(3):194-9. doi: 10.1016/S1684-1182(10)60031-X.</citation>
    <PMID>21291846</PMID>
  </reference>
  <reference>
    <citation>Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013 Nov;42(5):403-9. doi: 10.1016/j.ijantimicag.2013.07.018. Epub 2013 Sep 7.</citation>
    <PMID>24071027</PMID>
  </reference>
  <reference>
    <citation>Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014 Apr;27(2):200-10. doi: 10.1097/QCO.0000000000000038. Review.</citation>
    <PMID>24573013</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009 Nov;136(5):1237-1248. doi: 10.1378/chest.09-0087. Epub 2009 Aug 20.</citation>
    <PMID>19696123</PMID>
  </reference>
  <reference>
    <citation>Spoorenberg V, Hulscher ME, Akkermans RP, Prins JM, Geerlings SE. Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis. 2014 Jan;58(2):164-9. doi: 10.1093/cid/cit688. Epub 2013 Oct 24.</citation>
    <PMID>24158412</PMID>
  </reference>
  <reference>
    <citation>Levison ME, Kaye D. Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens. Curr Infect Dis Rep. 2013 Apr;15(2):109-15. doi: 10.1007/s11908-013-0315-7.</citation>
    <PMID>23378123</PMID>
  </reference>
  <reference>
    <citation>Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs. 1997 Apr;53(4):583-92. Review.</citation>
    <PMID>9098661</PMID>
  </reference>
  <reference>
    <citation>Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002 Jul 8;113 Suppl 1A:5S-13S. Review.</citation>
    <PMID>12113866</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In Evaluation of chemotherapeutic agents. Edited by MacLeod CM. New York: Columbia University Press; 1949:191-205.</citation>
  </reference>
  <reference>
    <citation>Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004 Oct;9(4):197-204.</citation>
    <PMID>15509405</PMID>
  </reference>
  <reference>
    <citation>Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27.</citation>
    <PMID>21793988</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigació Biomèdica de Bellvitge</investigator_affiliation>
    <investigator_full_name>Miquel Pujol</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>UTI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

